Lineage Cell Therapeutics, Inc. (LCTX)
$1.11-$0.05 (-4.31%) Today
Neal C. Bradsher - DirectorLineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 750,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Nov 22, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Neal C. Bradsher - Director | Grant or award | OPTION TO PURCHASE COMMON SHARES | 125,000 | $0.00 | - | |
| Anula Jayasuriya | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Michael H. Mulroy | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
 Deborah J. Andrews | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Angus C. Russell | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Dipti Amin | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Brian M. Culley - Officer | Open-market purchase | Common Shares | 15,000 | $1.63 | $24K | |
| Brian M. Culley - Officer | Grant or award | Employee Stock Option (Right to Buy) | 3,250,000 | $0.00 | - | |
| Jill Ann Howe - Officer | Grant or award | Employee Stock Option (Right to Buy) | 1,050,000 | $0.00 | - | |
| George A. Samuel III - Officer | Grant or award | Employee Stock Option (Right to Buy) | 900,000 | $0.00 | - | |
| Brian M. Culley - Officer | Option exercise | Common Shares | 31,250 | - | - | |
| Brian M. Culley - Officer | Tax withholding / forfeiture | Common Shares | 12,869 | $1.80 | $23K | |
| Brian M. Culley - Officer | Option exercise | Restricted Stock Units | 31,250 | $0.00 | - | |
| George A. Samuel III - Officer | Option exercise | Common Shares | 6,075 | - | - | |
| George A. Samuel III - Officer | Tax withholding / forfeiture | Common Shares | 2,502 | $1.80 | $5K | |
| George A. Samuel III - Officer | Option exercise | Restricted Stock Units | 6,075 | $0.00 | - | |
| Brian M. Culley - Officer | Grant or award | Common Shares | 8,925 | - | - | |
| Brian M. Culley - Officer | Tax withholding / forfeiture | Common Shares | 334 | $1.68 | $561 | |
| George A. Samuel III - Officer | Grant or award | Common Shares | 1,735 | - | - | |
| George A. Samuel III - Officer | Tax withholding / forfeiture | Common Shares | 65 | $1.68 | $109 | |
| Neal C. Bradsher - Director | Grant or award | OPTION TO PURCHASE COMMON SHARES | 75,000 | $0.00 | - | |
| Deborah J. Andrews | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Michael H. Mulroy | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Angus C. Russell | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Anula Jayasuriya | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Dipti Amin | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Jill Ann Howe - Officer | Open-market purchase | Common Shares | 15,000 | $0.59 | $9K | |
| George A. Samuel III - Officer | Open-market purchase | Common Shares | 15,000 | $0.60 | $9K | |
| Michael H. Mulroy | Open-market purchase | Common Shares | 40,000 | $0.57 | $23K | |
| Brian M. Culley - Officer | Open-market purchase | Common Shares | 40,000 | $0.60 | $24K |
Lineage Cell Therapeutics, Inc. (LCTX) had 6 insider filings in the last 90 days, with the most recent on 2026-07-02. The full record for LCTX runs to 24 Form 4 filings, the earliest from 2024-11-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LCTX were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of LCTX were filed in the last 90 days.
This page tracks LCTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LCTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
